Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer's and Parkinson's diseases, has reported third-quarter 2026 corporate updates, highlighting progress in its pivotal Phase 3 DUET-AD trial and preparations for a planned New Drug Application (NDA). The announcement places the company's lead drug candidate on a defined timeline toward a critical data readout that could shape its regulatory future and, if successful, offer a new oral treatment option for early Alzheimer's disease.
The DUET-AD trial is fully enrolled with 862 patients with early Alzheimer's disease and features two prespecified efficacy readouts at six and 18 months to evaluate symptomatic and disease-modifying effects, respectively. Annovis expects topline results from the six-month treatment period in March 2027 and plans to begin transitioning eligible patients into its Alzheimer's open-label extension study by the end of November 2026. The dual-readout design is notable because it aims to distinguish between a symptomatic benefit and a potential disease-modifying effect, a distinction that could influence both clinical interpretation and the eventual regulatory package.
Annovis also reported enrollment of 326 patients in its Parkinson's disease open-label extension study, which is designed to evaluate the long-term safety and efficacy of buntanetap over 36 months. In September, the company partnered with Weave Bio to support regulatory documentation and preparation of its planned NDA. Annovis subsequently closed an approximately $21 million underwritten public offering on Nov. 6, 2026, including a $5 million investment from its board chairman. Management said the financing is expected to support operations through the anticipated March 2027 topline data readout.
The financing update is significant for investors because it addresses a central risk in clinical-stage biotechnology: funding runway through a major data event. A $21 million raise, bolstered by insider participation, suggests the company has secured the resources it believes are necessary to reach the readout without an immediate additional capital raise. For readers tracking the neurodegenerative disease space, the March 2027 data could also inform the broader effort to develop therapies that target multiple neurotoxic proteins rather than a single pathway.
Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company is headquartered in Malvern, Pennsylvania, and its pipeline spans Alzheimer's disease (AD) and Parkinson's disease (PD).
Annovis Bio (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, and its progress can be followed through its website at www.annovisbio.com. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The full press release can be viewed at https://ibn.fm/6c61g.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.

